{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:42:02Z","timestamp":1793072522498,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A licensed chikungunya vaccine now exists; however, it remains unclear whether it could be deployed during outbreaks to reduce the health burden. We used an epidemic in Paraguay as a case study. We conducted a seroprevalence study and used models to reconstruct epidemic transmission dynamics, providing a framework to assess the theoretical impact of a vaccine had it been available. We estimated that 33.0% (95% confidence interval (CI) 30.1\u201336.0%) of the population became infected during the outbreak. Of these individuals, 6.3% (95% CI 5.8\u20136.9%) were detected by the surveillance system, with a mean infection fatality ratio of 0.013% (95% CI 0.012\u20130.014%). A disease-blocking vaccine with 75% efficacy deployed in 40% of individuals aged \u226512 years over a 3-month period would have prevented 34,200 (95% CI 30,900\u201338,000) cases, representing 23% of all cases, and 73 (95% CI 66\u201381) deaths. If the vaccine also leads to infection blocking, 88% of cases would have been averted. These findings suggest that the vaccine is an important new tool to control outbreaks.<\/jats:p>","DOI":"10.1038\/s41591-025-03684-w","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T05:03:28Z","timestamp":1746075808000},"page":"2335-2341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Modeling the impact of vaccine campaigns on the epidemic transmission dynamics of chikungunya virus outbreaks"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3143-0751","authenticated-orcid":false,"given":"Pastor E.","family":"P\u00e9rez-Estigarribia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4668-8755","authenticated-orcid":false,"given":"Gabriel","family":"Ribeiro dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9186-4549","authenticated-orcid":false,"given":"Simon","family":"Cauchemez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Karina","family":"Ibarrola-Vannucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Sequera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Villalba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1187-7110","authenticated-orcid":false,"given":"Jose Luis","family":"Di Fabio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Scarponi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christinah","family":"Mukandavire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7154-5505","authenticated-orcid":false,"given":"Arminder","family":"Deol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1gueda","family":"Cabello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsi","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyntia","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liz","family":"Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3626-4254","authenticated-orcid":false,"given":"Henrik","family":"Salje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,1]]},"reference":[{"key":"3684_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.antiviral.2015.04.016","volume":"120","author":"SC Weaver","year":"2015","unstructured":"Weaver, S. C. & Forrester, N. L. Chikungunya: evolutionary history and recent epidemic spread. Antiviral Res. 120, 32\u201339 (2015).","journal-title":"Antiviral Res."},{"key":"3684_CR2","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/S1473-3099(23)00810-1","volume":"24","author":"H Kang","year":"2024","unstructured":"Kang, H. et al. Chikungunya seroprevalence, force of infection, and prevalence of chronic disability after infection in endemic and epidemic settings: a systematic review, meta-analysis, and modelling study. Lancet Infect. Dis. 24, 488\u2013503 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"3684_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijid.2021.08.066","volume":"112","author":"M O\u2019Driscoll","year":"2021","unstructured":"O\u2019Driscoll, M., Salje, H., Chang, A. Y. & Watson, H. Arthralgia resolution rate following chikungunya virus infection. Int. J. Infect. Dis. 112, 1\u20137 (2021).","journal-title":"Int. J. Infect. Dis."},{"key":"3684_CR4","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S1473-3099(24)00029-X","volume":"24","author":"H Salje","year":"2024","unstructured":"Salje, H. & Cort\u00e9s Azuero, O. The deadly potential of chikungunya virus. Lancet Infect. Dis. 24, 442\u2013444 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"3684_CR5","doi-asserted-by":"publisher","first-page":"e319","DOI":"10.1016\/S2666-5247(23)00033-2","volume":"4","author":"WM de Souza","year":"2023","unstructured":"de Souza, W. M. et al. Spatiotemporal dynamics and recurrence of chikungunya virus in Brazil: an epidemiological study. Lancet Microbe 4, e319\u2013e329 (2023).","journal-title":"Lancet Microbe"},{"key":"3684_CR6","first-page":"2241","volume":"330","author":"E Harris","year":"2023","unstructured":"Harris, E. FDA approves first chikungunya vaccine. JAMA 330, 2241 (2023).","journal-title":"JAMA"},{"key":"3684_CR7","unstructured":"Gavi, the Vaccine Alliance. More than US$ 1.8 billion in support for African vaccine manufacturing, catching up missed children and pandemic preparedness approved as Gavi Board steps up efforts to tackle backsliding and fight health emergencies. Gavi.org https:\/\/www.gavi.org\/news\/media-room\/initiatives-african-vaccine-manufacturing-approved-gavi-board (2023)."},{"key":"3684_CR8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/21645515.2016.1245250","volume":"13","author":"SN Desai","year":"2017","unstructured":"Desai, S. N. et al. Achievements and challenges for the use of killed oral cholera vaccines in the global stockpile era. Hum. Vaccin. Immunother. 13, 579\u2013587 (2017).","journal-title":"Hum. Vaccin. Immunother."},{"key":"3684_CR9","doi-asserted-by":"publisher","first-page":"e0004101","DOI":"10.1371\/journal.pntd.0004101","volume":"9","author":"G Kuno","year":"2015","unstructured":"Kuno, G. A re-examination of the history of etiologic confusion between dengue and chikungunya. PLoS Negl. Trop. Dis. 9, e0004101 (2015).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"3684_CR10","doi-asserted-by":"publisher","first-page":"e0003764","DOI":"10.1371\/journal.pntd.0003764","volume":"9","author":"I-K Yoon","year":"2015","unstructured":"Yoon, I.-K. et al. High rate of subclinical chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines. PLoS Negl. Trop. Dis. 9, e0003764 (2015).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"3684_CR11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/infdis\/jiac246","volume":"227","author":"JK Lim","year":"2023","unstructured":"Lim, J. K. et al. Seroepidemiological reconstruction of long-term chikungunya virus circulation in Burkina Faso and Gabon. J. Infect. Dis. 227, 261\u2013267 (2023).","journal-title":"J. Infect. Dis."},{"key":"3684_CR12","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.3201\/eid2909.230523","volume":"29","author":"M Giovanetti","year":"2023","unstructured":"Giovanetti, M. et al. Rapid epidemic expansion of chikungunya virus East\/Central\/South African lineage, Paraguay. Emerg. Infect. Dis. 29, 1859\u20131863 (2023).","journal-title":"Emerg. Infect. Dis."},{"key":"3684_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.18004\/anales\/2023.056.01.19","volume":"56","author":"G Sequera","year":"2023","unstructured":"Sequera, G. \u00bfPor qu\u00e9 esta gran epidemia de Chikungunya? \u00bfQu\u00e9 paso del Dengue? Fac. Cienc. M\u00e9d. (Asunci\u00f3n) 56, 19\u201324 (2023).","journal-title":"Fac. Cienc. M\u00e9d. (Asunci\u00f3n)"},{"key":"3684_CR14","unstructured":"Guti\u00e9rrez, L. A. PAHO\/WHO data\u2014weekly report. Pan American Health Organization\/World Health Organization https:\/\/www3.paho.org\/data\/index.php\/en\/mnu-topics\/chikv-en\/550-chikv-weekly-en.html (2019)."},{"key":"3684_CR15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ijid.2020.03.073","volume":"95","author":"I-K Yoon","year":"2020","unstructured":"Yoon, I.-K. et al. Pre-existing chikungunya virus neutralizing antibodies correlate with risk of symptomatic infection and subclinical seroconversion in a Philippine cohort. Int. J. Infect. Dis. 95, 167\u2013173 (2020).","journal-title":"Int. J. Infect. Dis."},{"key":"3684_CR16","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1016\/S2666-5247(20)30175-0","volume":"2","author":"MS Kumar","year":"2021","unstructured":"Kumar, M. S. et al. Seroprevalence of chikungunya virus infection in India, 2017: a cross-sectional population-based serosurvey. Lancet Microbe 2, e41\u2013e47 (2021).","journal-title":"Lancet Microbe"},{"key":"3684_CR17","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/infdis\/jiv470","volume":"213","author":"H Salje","year":"2016","unstructured":"Salje, H. et al. Reconstruction of 60 years of chikungunya epidemiology in the Philippines demonstrates episodic and focal transmission. J. Infect. Dis. 213, 604\u2013610 (2016).","journal-title":"J. Infect. Dis."},{"key":"3684_CR18","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/S0140-6736(23)00641-4","volume":"401","author":"M Schneider","year":"2023","unstructured":"Schneider, M. et al. Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 401, 2138\u20132147 (2023).","journal-title":"Lancet"},{"key":"3684_CR19","first-page":"100673","volume":"30","author":"WM de Souza","year":"2024","unstructured":"de Souza, W. M. et al. Chikungunya: a decade of burden in the Americas. Lancet Reg. Health Am. 30, 100673 (2024).","journal-title":"Lancet Reg. Health Am."},{"key":"3684_CR20","doi-asserted-by":"publisher","first-page":"13420","DOI":"10.1073\/pnas.1611391113","volume":"113","author":"H Salje","year":"2016","unstructured":"Salje, H. et al. How social structures, space, and behaviors shape the spread of infectious diseases using chikungunya as a case study. Proc. Natl Acad. Sci. USA 113, 13420\u201313425 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3684_CR21","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1038\/s41467-020-16516-x","volume":"11","author":"N Hoz\u00e9","year":"2020","unstructured":"Hoz\u00e9, N. et al. Reconstructing Mayaro virus circulation in French Guiana shows frequent spillovers. Nat. Commun. 11, 2842 (2020).","journal-title":"Nat. Commun."},{"key":"3684_CR22","doi-asserted-by":"publisher","first-page":"e0243239","DOI":"10.1371\/journal.pone.0243239","volume":"15","author":"ARS P\u00e9riss\u00e9","year":"2020","unstructured":"P\u00e9riss\u00e9, A. R. S. et al. Zika, dengue and chikungunya population prevalence in Rio de Janeiro city, Brazil, and the importance of seroprevalence studies to estimate the real number of infected individuals. PLoS ONE 15, e0243239 (2020).","journal-title":"PLoS ONE"},{"key":"3684_CR23","doi-asserted-by":"publisher","first-page":"211498","DOI":"10.1098\/rsos.211498","volume":"9","author":"CJE Metcalf","year":"2022","unstructured":"Metcalf, C. J. E. et al. Comparing the age and sex trajectories of SARS-CoV-2 morbidity and mortality with other respiratory pathogens. R. Soc. Open Sci. 9, 211498 (2022).","journal-title":"R. Soc. Open Sci."},{"key":"3684_CR24","doi-asserted-by":"publisher","first-page":"636","DOI":"10.15585\/mmwr.mm7223a5","volume":"72","author":"M Torales","year":"2023","unstructured":"Torales, M. et al. Notes from the field: chikungunya outbreak\u2014Paraguay, 2022\u20132023. MMWR Morb. Mortal. Wkly. Rep. 72, 636\u2013638 (2023).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"3684_CR25","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.mbs.2013.10.007","volume":"246","author":"A Pandey","year":"2013","unstructured":"Pandey, A., Mubayi, A. & Medlock, J. Comparing vector\u2013host and SIR models for dengue transmission. Math. Biosci. 246, 252\u2013259 (2013).","journal-title":"Math. Biosci."},{"key":"3684_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1093\/infdis\/jiad468","volume":"229","author":"A Andronico","year":"2024","unstructured":"Andronico, A. et al. Comparing the performance of three models incorporating weather data to forecast dengue epidemics in Reunion Island, 2018\u20132019. J. Infect. Dis. 229, 10\u201318 (2024).","journal-title":"J. Infect. Dis."},{"key":"3684_CR27","doi-asserted-by":"publisher","first-page":"taae123","DOI":"10.1093\/jtm\/taae123","volume":"31","author":"LH Chen","year":"2024","unstructured":"Chen, L. H., Fritzer, A., Hochreiter, R., Dubischar, K. & Meyer, S. From bench to clinic: the development of VLA1553\/IXCHIQ, a live-attenuated chikungunya vaccine. J. Travel Med. 31, taae123 (2024).","journal-title":"J. Travel Med."},{"key":"3684_CR28","doi-asserted-by":"publisher","first-page":"taad156","DOI":"10.1093\/jtm\/taad156","volume":"31","author":"R McMahon","year":"2024","unstructured":"McMahon, R. et al. A randomized, double-blinded phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults. J. Travel Med. 31, taad156 (2024).","journal-title":"J. Travel Med."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03684-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03684-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03684-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T12:15:41Z","timestamp":1757160941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03684-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3684"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03684-w","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,1]]},"assertion":[{"value":"11 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.R.d.S. and H.S. are paid consultants for Valneva in support of their Phase IV studies. H.S. has also received consultancy support from the Gavi Alliance. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}